Two-Track Obesity Care

Two-Track Obesity Care: How GLP-1 Access Split by Payer Just as the Pills Arrived

As oral pills and Medicare coverage make GLP-1 weight-loss drugs look universal, US access is dividing by payer rather than spreading evenly. The exposure runs to a 2028 coverage cliff across pharma, payers, employers and providers.

The consensus on obesity drugs reads like a victory lap: prices are falling, a pill has arrived, and Medicare is covering weight-loss treatment for the first time. The 2026 detail underneath is less tidy. Access is not spreading evenly; it is dividing by who pays. A subsidised but time-limited Medicare benefit sits beside a manufacturer cash market, while most state Medicaid programmes exclude these drugs and some employers are dropping them. The same pill can cost fifty dollars, several hundred, or be out of reach, depending only on coverage. The question for the next two years is not whether GLP-1s go mainstream, but which patients the system will pay for.

Signal Identification

This is an emerging payment-and-coverage inflection, not a clinical one. The binding variable is the payer: the same FDA-approved drug carries a different price, a different waiting list and a different expiry date depending on whether the patient is on Medicare, Medicaid, a commercial plan or paying cash. On current evidence those tracks are pulling apart rather than converging, and a hard transition in 2027 could widen the gap further.

Time horizon: 1–3 years (live now; the coverage cliff bites at the end of 2027 into 2028) Plausibility band: Medium–High Geographic / Jurisdictional Scope: United States, across the Medicare, Medicaid, commercial-employer and cash/direct-to-consumer payer tracks; global spillover via manufacturer reference pricing. Sectors exposed: Pharma and biopharma, health insurers and PBMs, employer benefits, providers and primary care, telehealth and direct-to-consumer pharmacy; with downstream effects on food and beverage and medtech.

What's Changing

Medicare has opened a door it kept shut for two decades, but only part way. CMS will cover certain weight-loss GLP-1s for $50 a month under the Medicare GLP-1 Bridge, a demonstration running only from July 2026 to December 2027 (Centers for Medicare & Medicaid Services, 06/05/2026). The benefit is ring-fenced: because it sits outside the Part D benefit, the $50 copay does not count toward the deductible or the $2,100 out-of-pocket cap, and low-income beneficiaries cannot apply their Part D subsidy to it (KFF, 09/03/2026).

Supply, meanwhile, is widening fast. The FDA approved Foundayo, a new oral GLP-1 pill, just 50 days after filing, its fastest new-molecule clearance since 2002 (U.S. Food and Drug Administration, 01/04/2026). J.P. Morgan projects the global GLP-1 market reaching $200 billion by 2030 and roughly 30 million American users, up from about 10 million in 2025, as pills and lower prices broaden reach (J.P. Morgan, 27/02/2026). Yet cash prices still run from $149 to $699 a month, and about half of users say the drugs are hard to afford (KFF Health News, 06/05/2026).

The bottom track is narrowing. The number of state Medicaid programmes covering obesity GLP-1s has fallen to 13 this year from 16, with California, New Hampshire, Pennsylvania and South Carolina cutting coverage and Michigan restricting it to save an estimated $240 million (Stateline, 30/04/2026). Coverage stays optional for states even though almost four in ten adults with Medicaid have obesity, and about 55% of commercial employers cover the drugs while 15% of those have already dropped them (KFF, 16/01/2026).

One drug, four payer tracks: US obesity-GLP-1 access in 2026

Sources: Centers for Medicare & Medicaid Services (06/05/2026); J.P. Morgan (27/02/2026); KFF (16/01/2026); Stateline (30/04/2026). Bar widths are indicative.

Disruption Pathway

The pathway runs in three stages. Through 2026 to 2027, the tracks diverge: the Medicare Bridge goes live, the cash and direct-to-consumer market grows around insurance, and budget-strained states keep trimming Medicaid coverage. In 2027 the cliff arrives. The Bridge expires in December and is meant to hand off to a voluntary demonstration, the BALANCE model, but plan participation is uncertain, so beneficiaries may have to switch Part D plans to keep coverage (KFF, 09/03/2026). By 2028 the system either settles into a durable two-track entitlement or snaps back if the voluntary model is under-subscribed and the Bridge is not renewed.

Stresses concentrate at three points: Medicaid and low-income patients, who stay excluded despite high obesity rates; Medicare beneficiaries facing a 2027 handoff with no guaranteed successor; and insurers, who would inherit billions in cost if a permanent benefit shifts spending from government to plans (KFF Health News, 06/05/2026). Two adaptations follow. Manufacturers deepen their cash and direct-to-consumer channels, routing demand around insurance. Payers and states ration through prior authorisation and tighter clinical criteria, as Michigan did (Stateline, 30/04/2026).

Why This Matters

For pharma, insurers, employers, providers and investors, the planning assumption to retire is that GLP-1s become a single, universally reimbursed mass market. Demand will be large, but access and revenue will be segmented by payer and politically contingent, with a reset point in late 2027. Manufacturers should weight a growing cash channel and a possible Medicare snap-back; insurers should price the cost they would absorb if the Bridge becomes permanent; employers face the same affordability maths that has already pushed some to drop coverage. The decision-relevant horizon is not 2030; it is the 2027-2028 cliff.

Decision-action posture for this signal: Prepare — the split is live but its resolution turns on the 2027 BALANCE transition, leaving time to model payer-segmented demand and commit on named triggers.

Counter-Argument

The strongest objection is that access is plainly expanding, not splitting. Medicare is covering obesity treatment for the first time, the FDA has cleared an oral pill at record speed, cash prices have fallen toward $149 a month, and J.P. Morgan projects roughly 30 million US users by 2030 on a $200 billion global market (J.P. Morgan, 27/02/2026). On that reading the trend is democratisation.

But expansion and bifurcation are not opposites here; the market can grow while access forks. The Medicare benefit is time-limited and excluded from the out-of-pocket cap, Medicaid coverage is shrinking to 13 states, employers are dropping it, and the lowest-income patients remain priced out even at cash rates. A market that doubles while a third of payers retreat is not universal access; it is a two-track system with more people on the top track, and a cliff under the public one.

Implications

On the available evidence, this catalyses a durable, payer-segmented obesity-care market and a cash channel that routes around insurance, rather than the single reimbursed market the headlines imply. The inflection window is 2026 to 2028: live now, decided at the 2027 handoff. Manufacturers with strong direct-to-consumer reach and patients on Medicare or able to pay cash gain; Medicaid and low-income enrollees carry the downside. The binding question is which track each cohort lands on, and whether the public track survives 2027.

Early Indicators to Monitor

Part D plan sign-up rates for the voluntary BALANCE model ahead of the 2027 open-enrolment transition.
Whether CMS renews or replaces the Medicare GLP-1 Bridge before its December 2027 expiry.
Further state Medicaid programmes dropping or restricting obesity GLP-1 coverage below the current 13.
Manufacturer cash and direct-to-consumer volumes growing faster than insured prescriptions.
Commercial employers beyond the current 15% cutting GLP-1 weight-loss coverage at 2027 renewal.

Disconfirming Signals

A permanent, mandatory Medicare obesity benefit replacing the time-limited Bridge with cap-counted cost-sharing.
A federal requirement that state Medicaid programmes cover obesity GLP-1s, reversing the retreat.
Cash and list prices falling far enough that payer track stops determining access.
Commercial coverage broadening back above prior levels as costs ease with competition.
BALANCE securing broad plan participation, making the 2027 handoff smooth rather than a cliff.

Strategic Questions

Should manufacturers build forecasts on insured coverage, or weight the cash channel and a 2027 Medicare reset?
At what BALANCE participation rate does the 2027 handoff move from a risk to manage to a cliff to plan around?
Which patient cohorts should providers expect to lose access first if the public track is not renewed?

Keywords

GLP-1; obesity drugs; Medicare GLP-1 Bridge; Medicaid coverage; weight-loss drugs; orforglipron; direct-to-consumer pharmacy; drug access; BALANCE model; payer coverage; oral GLP-1; health equity

Bibliography

Source tiers: Tier 1, governments, regulators and intergovernmental bodies. Tier 2, think-tanks, academic institutes, major consultancies and quality data providers. Tier 3, quality journalism and specialist trade press. Tier 4, vendor, company and practitioner sources, used only as directional corroboration.

Tier 1 Coming Soon: CMS to Provide $50 Monthly Access to GLP-1 Medications for Medicare Beneficiaries. Centers for Medicare & Medicaid Services (06/05/2026).
Tier 1 FDA Approves First New Molecular Entity Under National Priority Voucher Program. U.S. Food and Drug Administration (01/04/2026).
Tier 2 How demand for (and supply of) weight loss drugs is playing out in 2026. J.P. Morgan (27/02/2026).
Tier 2 Medicaid Coverage of and Spending on GLP-1s. KFF (16/01/2026).
Tier 2 What Medicare's Temporary Program Covering GLP-1s for Obesity Means for Beneficiaries. KFF (09/03/2026).
Tier 3 A new Medicare option for weight loss drugs is coming: Here's what to know. KFF Health News (06/05/2026).
Tier 3 More states consider dropping GLP-1 weight loss drugs from Medicaid. Stateline (30/04/2026).